Fidelity Investments’s Enveric Biosciences ENVB Stock Holding History

Fidelity Investments’s Portfolio ENVB Stock Details ENVB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$3	Buy	+2	New	+$3	﹤0.01%	5751
2025 Q2	–	Sell	-286	Closed	-$4.76K	–	5375
2025 Q1	$4.76K	Buy	+286	New	+$9.9K	﹤0.01%	4719
2024 Q3	–	Sell	-1	Closed	-$74	–	5554
2024 Q2	$74	Buy	+1	New	+$151	﹤0.01%	5000
2022 Q4	–	Hold	0	–	-$4	–	5408
2022 Q3	–	Hold	0	–	–	–	5271
2022 Q2	–	Hold	0	–	–	–	5341
2021 Q3	–	Hold	0	–	–	–	4516
2021 Q2	–	Hold	0	–	–	–	4404

Other funds holding ENVB

AdvisorShares Investments Bethesda, Maryland $796M AUM 17.24% 1-Year Est. Return

StoneX Group New York $2.75B AUM 24.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.38B AUM 56.37% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Root Financial Partners Encinitas, California $2.98B AUM 13.9% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

Danske Bank Copenhagen K, Denmark $50.1B AUM 35.17% 1-Year Est. Return

Fidelity Investments's ENVB Position: Q3 2026 in Review

Fidelity Investments opened a new position in Enveric Biosciences (ENVB) in Q3 2026: 2 shares worth $3. The stake represents ﹤0.01% of the portfolio and ranks #5751 among its holdings. This is a return to the name: Fidelity Investments previously reported a position in ENVB as recently as Q1 2025.

Fidelity Investments first reported a position in ENVB in Q2 2024 and has held it in 3 quarters since. The position peaked at $4.76K in Q1 2025. 10 funds tracked by Wall St. Rank hold ENVB as of Q3 2026.

Fidelity Investments held 2 shares of Enveric Biosciences worth $3 as of Q3 2026.
Enveric Biosciences was a new Fidelity Investments position in Q3 2026.
Enveric Biosciences made up ﹤0.01% of Fidelity Investments's portfolio in Q3 2026, its #5751 holding.
Fidelity Investments first reported a position in Enveric Biosciences in Q2 2024 and has held it in 3 quarters since.
Fidelity Investments's Enveric Biosciences position peaked at $4.76K in Q1 2025.
10 funds tracked by Wall St. Rank held Enveric Biosciences as of Q3 2026.

Based on Fidelity Investments's 13F filing for Q3 2026, filed 10 Nov 2026.